Clinical and economic impact of implementing OVIVA criteria on patients with bone and joint infections in OPAT

Michael Marks, Lucy C K Bell, Imogen Jones, Tommy Rampling, Katharina Kranzer, Stephen Morris-Jones, Sarah Logan, Gabriele Pollara
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2019 October 11
The OVIVA study demonstrated non-inferiority for managing bone and joint infections (BJI) with oral antibiotics. We report that 79.7% of OPAT patients being treated for BJI at our centre would be eligible for oral antibiotics, saving median 19.5 IV antibiotic days (IQR 8.5-37) and GBP 1,234 (IQR 569-2,594) per patient.


You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Available on the App Store

Available on the Play Store
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"